Molecular markers of systemic therapy response in urothelial carcinoma

Asian J Urol. 2021 Oct;8(4):376-390. doi: 10.1016/j.ajur.2021.05.001. Epub 2021 May 14.

Abstract

Identification of reliable molecular biomarkers that can complement clinical practice represents a fascinating challenge in any cancer field. Urothelial carcinoma is a very heterogeneous disease and responses to systemic therapies, and outcomes after radical cystectomy are difficult to predict. Advances in molecular biology such as next generation sequencing and whole genome or transcriptomic analysis provide promising platforms to achieve a full understanding of the biology behind the disease and can identify emerging predictive biomarkers. Moreover, the ability to categorize patients' risk of recurrence after curative treatment, or even predict benefit from a conventional or targeted therapies, represents a compelling challenge that may reshape both selection for tailored treatment and disease monitoring. Progress has been made but currently no molecular biomarkers are used in the clinical setting to predict response to systemic agents in either neoadjuvant or adjuvant settings highlighting a relevant unmet need. Here, we aim to present the emerging role of molecular biomarkers in predicting response to systemic agents in urothelial carcinoma.

Keywords: Adjuvant chemotherapy; Biomarkers; Neoadjuvant chemotherapy; Precision oncology; Targeted therapies; Urothelial carcinoma.

Publication types

  • Review